Drugs / Alpha-Lactalbumin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07629895 | Sep 2026 → Apr 2027 expected | polycystic ovary syndrome | Quaid-e-Azam Medical College | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-06-26 | Anixa Biosciences, Inc. | Results Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium anixa.com ↗ |
| 2026-06-11 | Anixa Biosciences, Inc. | Results Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium anixa.com ↗
Breast cancer vaccine presentation to include final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74% of participants |
| 2025-12-11 | Anixa Biosciences, Inc. | Results Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants anixa.com ↗
Final Phase 1 findings showed the investigational vaccine met all major primary endpoints, was safe and well tolerated at the maximum tolerated dose (MTD), and elicited protocol-defined immune responses in 74% of participants. |
| 2024-11-08 | Anixa Biosciences, Inc. | Results Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting anixa.com ↗
Protocol defined immune responses were exhibited in over 70% of patients |
| 2023-12-06 | Anixa Biosciences, Inc. | Results Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine anixa.com ↗
Among the doses studied, Dose Level 1 (10 mcg α-lactalbumin/10 mcg zymosan) was determined to be a usable immunologic dose as well as the maximum tolerated dose (MTD). |
| 2020-11-23 | Anixa Biosciences, Inc. | Regulatory Anixa Biosciences and Cleveland Clinic File IND Application for Breast Cancer Vaccine anixa.com ↗
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that an IND (Investigational New Drug) application for its prophylactic breast cancer vaccine has been filed with the U.S. Food and Drug Administration. |
All press releases naming this drug 6 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alpha-Lactalbumin | “Alpha-lactalbumin 50 mg administered orally twice daily in combination with myo-inositol for 12 weeks.” NCT07629895 ↗ |
| Known as | α-lactalbumin | “The combination with the milk protein α-lactalbumin can be a useful therapeutic approach to overcome inositol resistance and achieve ovulation in these women.” PMID 37367875 ↗ May 2023 |
| Modality | Protein / enzyme biologic | “Alpha-lactalbumin, a whey protein fraction, has been reported to enhance intestinal absorption and bioavailability of myo-inositol, potentially leading to improved therapeutic outcomes.” NCT07629895 ↗ |
| Route | Oral | “Alpha-lactalbumin 50 mg administered orally twice daily in combination with myo-inositol for 12 weeks.” NCT07629895 ↗ |